| Identification | Back Directory | [Name]
nBu-CAyl-{Cys(tMeBn(DOTA-AET)-Pro-Pro-Thr-GIn-Phe-Cys}-OH | [CAS]
2803421-14-7 | [Synonyms]
3BP-3940
nBu-CAyl-{Cys(tMeBn(DOTA-AET)-Pro-Pro-Thr-GIn-Phe-Cys}-OH | [Molecular Formula]
C66H98N14O18S3 | [MOL File]
2803421-14-7.mol | [Molecular Weight]
1471.77 |
| Chemical Properties | Back Directory | [Boiling point ]
1689.2±65.0 °C(predicted) | [density ]
1.44±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [form ]
Solid | [pka]
1.83±0.10(predicted) | [color ]
White to off-white | [Sequence]
nBu-CAyl-{Cys(tMeBn(DOTA-AET)-Pro-Pro-Thr-GIn-Phe-Cys}-OH |
| Hazard Information | Back Directory | [Uses]
3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases[1][2]. | [IC 50]
RDC Peptide | [References]
[1] Greifenstein L, et al. 3BP-3940, a highly potent FAP-targeting peptide for theranostics-production, validation and first in human experience with Ga-68 and Lu-177. iScience. 2023 Nov 23;26 (12) :108541. DOI:10.1016/j.isci.2023.108541
[2] Kramer C S, et al. FAP-Peptidvermittelte Radiorezeptortherapie (PTRT) bei soliden Tumoren: erste klinische Erfahrungen mit dem 177Lu-, 225Ac-oder 90Y-markierten Peptid 3BP-3940[J]. Nuklearmedizin-NuclearMedicine, 2023, 62 (02) : V14. |
|
| Company Name: |
YantaiBio
|
| Tel: |
13758194781 |
| Website: |
|
|